title: [New perspectives for the treatment of age-related macular degeneration].
abstract: Currently, age-related macular degeneration (AMD) is untreatable, except for its neovascular complications. We review the primary pathogenesis of AMD and the pipeline of experimental interventions currently under way in clinical trials. They focus on four mechanisms: suppression of inflammation, visual cycle modification, prevention of oxidative damage and neuroprotection. Regulatory approval is years away, but the development may be accelerated by re-purposing of medications designed for systemic diseases.
authors.affiliation: Øjenafdelingen, Roskilde Sygehus, Køgevej 7-13, Roskilde. icm@dadlnet.dk
authors.forename: Irfan
authors.initials: I
authors.lastname: Rafique
authors.forename: Inger Christine
authors.initials: IC
authors.lastname: Munch
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D018696:Neuroprotective Agents / Q000627:therapeutic use
chemical_list: D000276:Adjuvants, Immunologic; D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000975:Antioxidants; D018696:Neuroprotective Agents